20668451	187	Kan Z	Diverse somatic mutation patterns and pathway alterations in human cancers.	Nature	2010	339
17611497	207	Carpten JD	A transforming mutation in the pleckstrin homology domain of AKT1 in cancer.	Nature	2007	373
17918180	207	Fraser M	Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.	International journal of cancer	2008	50
18504432	207	Bleeker FE	AKT1(E17K) in human solid tumours.	Oncogene	2008	55
19491896	207	Shoji K	The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.	British journal of cancer	2009	51
21216929	207	Janku F	PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors.	Molecular cancer therapeutics	2011	127
24440717	207	Janku F	Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.	Cell reports	2014	50
8622988	208	Cheng JQ	Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA.	Proceedings of the National Academy of Sciences of the United States of America	1996	143
22334387	367	Gottlieb B	The androgen receptor gene mutations database: 2012 update.	Human mutation	2012	64
19088202	580	Reid LJ	E3 ligase activity of BRCA1 is not essential for mammalian cell viability or homology-directed repair of double-strand DNA breaks.	Proceedings of the National Academy of Sciences of the United States of America	2008	53
25452441	580	Couch FJ	Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.	Journal of clinical oncology 	2015	60
19516027	668	Shah SP	Mutation of FOXL2 in granulosa-cell tumors of the ovary.	The New England journal of medicine	2009	125
22240241	668	Jamieson S	Molecular pathogenesis of granulosa cell tumors of the ovary.	Endocrine reviews	2012	30
7907678	672	Ford D	Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium.	Lancet	1994	261
9145676	672	Struewing JP	The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.	The New England journal of medicine	1997	316
9443863	672	Parmigiani G	Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2.	American journal of human genetics	1998	141
10359546	672	Peto J	Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.	Journal of the National Cancer Institute	1999	148
10883018	672	Holschneider CH	Ovarian cancer: epidemiology, biology, and prognostic factors.	Seminars in surgical oncology	2000	105
11179017	672	Risch HA	Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.	American journal of human genetics	2001	166
11257103	672	Welcsh PL	BRCA1 and BRCA2 and the genetics of breast and ovarian cancer.	Human molecular genetics	2001	114
11320250	672	Ruffner H	Cancer-predisposing mutations within the RING domain of BRCA1: loss of ubiquitin protein ligase activity and protection from radiation hypersensitivity.	Proceedings of the National Academy of Sciences of the United States of America	2001	96
11857015	672	Antoniou AC	A comprehensive model for familial breast cancer incorporating BRCA1, BRCA2 and other genes.	British journal of cancer	2002	106
12023992	672	Kauff ND	Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.	The New England journal of medicine	2002	167
12023993	672	Rebbeck TR	Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations.	The New England journal of medicine	2002	204
12237281	672	Thompson D	Cancer Incidence in BRCA1 mutation carriers.	Journal of the National Cancer Institute	2002	206
12483514	672	Jasin M	Homologous repair of DNA damage and tumorigenesis: the BRCA connection.	Oncogene	2002	94
12677558	672	Antoniou A	Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.	American journal of human genetics	2003	579
14576434	672	King MC	Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.	Science	2003	394
14981104	672	Rebbeck TR	Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group.	Journal of clinical oncology 	2004	146
15547178	672	Kennedy RD	The role of BRCA1 in the cellular response to chemotherapy.	Journal of the National Cancer Institute	2004	85
16014699	672	Tavtigian SV	Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral.	Journal of medical genetics	2006	168
16137750	672	Finch A	Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.	Gynecologic oncology	2006	73
16144895	672	Nelson HD	Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force.	Annals of internal medicine	2005	84
16284991	672	Pal T	BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.	Cancer	2005	156
16397213	672	Elstrodt F	BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.	Cancer research	2006	68
16484695	672	Chen S	Characterization of BRCA1 and BRCA2 mutations in a large United States sample.	Journal of clinical oncology 	2006	70
16522651	672	Deng CX	BRCA1: cell cycle checkpoint, genetic instability, DNA damage response and cancer evolution.	Nucleic acids research	2006	120
16835424	672	Finch A	Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.	JAMA	2006	93
16912212	672	Malone KE	Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in white and black American women ages 35 to 64 years.	Cancer research	2006	64
17117391	672	Lee Y	A candidate precursor to serous carcinoma that originates in the distal fallopian tube.	The Journal of pathology	2007	198
17148771	672	Risch HA	Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.	Journal of the National Cancer Institute	2006	127
17416853	672	Chen S	Meta-analysis of BRCA1 and BRCA2 penetrance.	Journal of clinical oncology 	2007	280
17456833	672	Crum CP	Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.	Clinical medicine and research	2007	64
17761984	672	Callahan MJ	Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction.	Journal of clinical oncology 	2007	100
17924331	672	Easton DF	A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes.	American journal of human genetics	2007	131
18034184	672	Fackenthal JD	Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations.	Nature reviews. Cancer	2007	108
18165636	672	Chetrit A	Effect of BRCA1/2 mutations on long-term survival of patients with invasive ovarian cancer: the national Israeli study of ovarian cancer.	Journal of clinical oncology 	2008	79
18268356	672	Kauff ND	Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.	Journal of clinical oncology 	2008	92
18342932	672	Folkins AK	A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.	Gynecologic oncology	2008	62
18349832	672	Antoniou AC	The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions.	British journal of cancer	2008	99
18955455	672	Tan DS	"BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations.	Journal of clinical oncology 	2008	101
19060844	672	Clarke B	Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.	Modern pathology 	2009	60
19141781	672	Rebbeck TR	Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.	Journal of the National Cancer Institute	2009	128
19241424	672	Hall MJ	BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer.	Cancer	2009	70
19298662	672	Young SR	The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.	BMC cancer	2009	55
19553641	672	Fong PC	Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.	The New England journal of medicine	2009	840
19636370	672	Brown PO	The preclinical natural history of serous ovarian cancer: defining the target for early detection.	PLoS medicine	2009	57
19841585	672	Kurian AW	BRCA1 and BRCA2 mutations across race and ethnicity: distribution and clinical implications.	Current opinion in obstetrics and gynecology	2010	41
19858402	672	Graeser MK	Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.	Journal of clinical oncology 	2009	52
19996028	672	Oktay K	Association of BRCA1 mutations with occult primary ovarian insufficiency: a possible explanation for the link between infertility and breast/ovarian cancer risks.	Journal of clinical oncology 	2010	57
20400477	672	O'Donovan PJ	BRCA1 and BRCA2: breast/ovarian cancer susceptibility gene products and participants in DNA double-strand break repair.	Carcinogenesis	2010	70
20516115	672	Lee MS	Comprehensive analysis of missense variations in the BRCT domain of BRCA1 by structural and functional assays.	Cancer research	2010	40
20606085	672	Hennessy BT	Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from poly (ADP ribose) polymerase inhibitors in ovarian cancer.	Journal of clinical oncology 	2010	67
20609467	672	Tutt A	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.	Lancet	2010	389
20609468	672	Audeh MW	Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.	Lancet	2010	309
20616022	672	Walsh T	Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2010	126
20810374	672	Domchek SM	Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.	JAMA	2010	187
21324516	672	Zhang S	Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer.	Gynecologic oncology	2011	52
21505135	672	Link DC	Identification of a novel TP53 cancer susceptibility mutation through whole-genome sequencing of a patient with therapy-related AML.	JAMA	2011	59
21717445	672	Schwartz MD	Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.	Cancer	2012	31
21987798	672	Konishi H	Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells.	Proceedings of the National Academy of Sciences of the United States of America	2011	47
21990146	672	Spurdle AB	ENIGMA--evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes.	Human mutation	2012	45
21990299	672	Yang D	Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.	JAMA	2011	104
22193408	672	Roy R	BRCA1 and BRCA2: different roles in a common pathway of genome protection.	Nature reviews. Cancer	2011	216
22203755	672	Kaye SB	Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer.	Journal of clinical oncology 	2012	94
22314128	672	Krepischi AC	Germline DNA copy number variation in familial and early-onset breast cancer.	Breast cancer research 	2012	31
22452356	672	Ledermann J	Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.	The New England journal of medicine	2012	200
22576213	672	Birkbak NJ	Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.	Cancer discovery	2012	44
22614657	672	Hartman AR	Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.	Cancer	2012	37
23233716	672	Weitzel JN	Prevalence and type of BRCA mutations in Hispanics undergoing genetic cancer risk assessment in the southwestern United States: a report from the Clinical Cancer Genetics Community Research Network.	Journal of clinical oncology 	2013	33
23257159	672	McLaughlin JR	Long-term ovarian cancer survival associated with mutation in BRCA1 or BRCA2.	Journal of the National Cancer Institute	2013	26
23257362	672	Verhaak RG	Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.	The Journal of clinical investigation	2013	106
23269703	672	Domchek SM	Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer.	Cancer discovery	2013	29
23628597	672	Mavaddat N	Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.	Journal of the National Cancer Institute	2013	94
23810788	672	Sandhu SK	The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.	The Lancet. Oncology	2013	84
23942203	672	Tarabeux J	Streamlined ion torrent PGM-based diagnostics: BRCA1 and BRCA2 genes as a model.	European journal of human genetics 	2014	21
24140203	672	Widschwendter M	The sex hormone system in carriers of BRCA1/2 mutations: a case-control study.	The Lancet. Oncology	2013	25
24218601	672	Etemadmoghadam D	Synthetic lethality between CCNE1 amplification and loss of BRCA1.	Proceedings of the National Academy of Sciences of the United States of America	2013	31
24225019	672	Lee JM	PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.	Annals of oncology 	2014	55
24292448	672	Phelan CM	Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study.	British journal of cancer	2014	23
24346285	672	Lee AJ	BOADICEA breast cancer risk prediction model: updates to cancer incidences, tumour pathology and web interface.	British journal of cancer	2014	21
24366376	672	Moyer VA	Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: U.S. Preventive Services Task Force recommendation statement.	Annals of internal medicine	2014	57
24366442	672	Nelson HD	Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation.	Annals of internal medicine	2014	33
24449235	672	Schwartz MD	Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.	Journal of clinical oncology 	2014	24
24478461	672	Laddha SV	Mutational landscape of the essential autophagy gene BECN1 in human cancers.	Molecular cancer research 	2014	37
24567435	672	Finch AP	Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.	Journal of clinical oncology 	2014	57
24618965	672	Dewey FE	Clinical interpretation and implications of whole-genome sequencing.	JAMA	2014	118
24824314	672	Friebel TM	Modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: systematic review and meta-analysis.	Journal of the National Cancer Institute	2014	23
25224030	672	Mersch J	Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian.	Cancer	2015	25
25348513	672	Zhong Q	Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.	Clinical cancer research 	2015	19
25366685	672	Kaufman B	Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.	Journal of clinical oncology 	2015	144
25398451	672	Candido-dos-Reis FJ	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer.	Clinical cancer research 	2015	16
25481791	672	Oza AM	Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial.	The Lancet. Oncology	2015	70
26187614	672	Kim G	FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of Chemotherapy.	Clinical cancer research 	2015	35
26426480	672	Armstrong J	Utilization and Outcomes of BRCA Genetic Testing and Counseling in a National Commercially Insured Population: The ABOUT Study.	JAMA oncology	2015	15
21768580	673	Ladabaum U	Strategies to identify the Lynch syndrome among patients with colorectal cancer: a cost-effectiveness analysis.	Annals of internal medicine	2011	71
22012135	673	Capper D	Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases.	Acta neuropathologica	2012	40
22608338	673	Falchook GS	Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.	Lancet	2012	179
22930283	673	Grisham RN	BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer.	Cancer	2013	27
26287849	673	Hyman DM	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.	The New England journal of medicine	2015	128
8968085	675	Goggins M	Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas.	Cancer research	1996	133
10433620	675	Breast Cancer Linkage Consortium.	Cancer risks in BRCA2 mutation carriers.	Journal of the National Cancer Institute	1999	251
16141007	675	van Asperen CJ	Cancer risks in BRCA2 families: estimates for sites other than breast and ovary.	Journal of medical genetics	2005	70
16793542	675	Xia B	Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2.	Molecular cell	2006	233
22274685	675	Bolton KL	Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer.	JAMA	2012	99
23165508	675	Barber LJ	Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.	The Journal of pathology	2013	40
9296497	1026	Somasundaram K	Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.	Nature	1997	106
11745677	1026	Piek JM	Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer.	The Journal of pathology	2001	132
25479140	1029	Grant RC	Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer.	Gastroenterology	2015	23
24270682	1302	Bouwman P	Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors?	Clinical cancer research 	2014	40
15761464	1499	Bell DA	Origins and molecular pathology of ovarian cancer.	Modern pathology 	2005	100
22653804	1499	McConechy MK	Use of mutation profiles to refine the classification of endometrial carcinomas.	The Journal of pathology	2012	45
23636398	1499	Cancer Genome Atlas Research Network.	Integrated genomic characterization of endometrial carcinoma.	Nature	2013	552
23765252	1499	McConechy MK	Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.	Modern pathology 	2014	25
23780408	1499	Bashashati A	Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.	The Journal of pathology	2013	80
15158434	1956	Roskoski R Jr	The ErbB/HER receptor protein-tyrosine kinases and cancer.	Biochemical and biophysical research communications	2004	70
16061871	1956	Schilder RJ	Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study.	Clinical cancer research 	2005	66
22649089	1956	Forshew T	Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA.	Science translational medicine	2012	209
23000897	1956	Cancer Genome Atlas Network.	Comprehensive molecular portraits of human breast tumours.	Nature	2012	2327
23563269	1956	Murtaza M	Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA.	Nature	2013	259
24366937	1956	Vergote IB	Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first-line platin-based chemotherapy for ovarian carcinoma: a European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group, and Gynecologic Cancer Intergroup study.	Journal of clinical oncology 	2014	23
24656976	1956	Yan M	HER2 aberrations in cancer: implications for therapy.	Cancer treatment reviews	2014	40
2470152	2064	Slamon DJ	Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.	Science	1989	1073
7657393	2064	Bellacosa A	Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas.	International journal of cancer	1995	174
22331459	2064	Stevens KN	19p13.1 is a triple-negative-specific breast cancer susceptibility locus.	Cancer research	2012	44
22899400	2064	Anglesio MS	Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas.	The Journal of pathology	2013	31
25682074	2064	Wong-Brown MW	Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer.	Breast cancer research and treatment	2015	17
9524123	2099	Migliaccio A	Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor.	The EMBO journal	1998	119
17525745	2263	Pollock PM	Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes.	Oncogene	2007	81
18636142	2263	Katoh M	Cancer genomics and genetics of FGFR2 (Review).	International journal of oncology	2008	50
21720365	2305	Cancer Genome Atlas Research Network.	Integrated genomic analyses of ovarian carcinoma.	Nature	2011	1665
22617326	2305	Szabova L	Perturbation of Rb, p53, and Brca1 or Brca2 cooperate in inducing metastatic serous epithelial ovarian cancer.	Cancer research	2012	34
21642682	2956	Bonadona V	Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome.	JAMA	2011	114
22331944	2956	Win AK	Colorectal and other cancer risks for carriers and noncarriers from families with a DNA mismatch repair gene mutation: a prospective cohort study.	Journal of clinical oncology 	2012	68
23091106	2956	Engel C	Risks of less common cancers in proven mutation carriers with lynch syndrome.	Journal of clinical oncology 	2012	32
24844595	2956	Meng B	POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endometrioid carcinoma of the endometrium.	Gynecologic oncology	2014	22
25238946	2956	Lancaster JM	Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.	Gynecologic oncology	2015	24
26657901	2956	Møller P	Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database.	Gut	2017	10
26720728	2956	Norquist BM	Inherited Mutations in Women With Ovarian Carcinoma.	JAMA oncology	2016	24
12644542	3845	Singer G	Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.	Journal of the National Cancer Institute	2003	164
23792451	3845	Ogino S	Discovery of colorectal cancer PIK3CA mutation as potential predictive biomarker: power and promise of molecular pathological epidemiology.	Oncogene	2014	38
8653691	4089	Schutte M	DPC4 gene in various tumor types.	Cancer research	1996	133
12097290	4089	Murphy KM	Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%.	Cancer research	2002	93
18398828	4292	Watson P	The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome.	International journal of cancer	2008	95
25224212	4292	Billingsley CC	Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing.	Cancer	2015	17
17908964	4609	Guan Y	Amplification of PVT1 contributes to the pathophysiology of ovarian and breast cancer.	Clinical cancer research 	2007	98
26315354	4683	Ramus SJ	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.	Journal of the National Cancer Institute	2015	22
22544022	4763	Carter SL	Absolute quantification of somatic DNA alterations in human cancer.	Nature biotechnology	2012	316
26017449	4763	Patch AM	Whole-genome characterization of chemoresistant ovarian cancer.	Nature	2015	123
15520168	5290	Campbell IG	Mutation of the PIK3CA gene in ovarian and breast cancer.	Cancer research	2004	221
16288007	5290	García-Rostán G	Mutation of the PIK3CA gene in anaplastic thyroid cancer.	Cancer research	2005	81
19349352	5290	Kuo KT	Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.	The American journal of pathology	2009	89
22157930	5290	Yamamoto S	Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations.	Modern pathology 	2012	43
22271473	5290	Janku F	PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations.	Journal of clinical oncology 	2012	145
20826764	5518	Jones S	Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.	Science	2010	317
10564676	5728	Ali IU	Mutational spectra of PTEN/MMAC1 gene: a tumor suppressor with lipid phosphatase activity.	Journal of the National Cancer Institute	1999	113
25190698	5728	Daly MB	Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.	Journal of the National Comprehensive Cancer Network 	2014	30
20400964	5888	Meindl A	Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene.	Nature genetics	2010	179
20729832	5888	Jensen RB	Purified human BRCA2 stimulates RAD51-mediated recombination.	Nature	2010	184
26261251	5888	Song H	Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.	Journal of clinical oncology 	2015	21
24141787	5889	Park JY	Breast cancer-associated missense mutants of the PALB2 WD40 domain, which directly binds RAD51C, RAD51 and BRCA2, disrupt DNA repair.	Oncogene	2014	24
24658001	6597	Ramos P	Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.	Nature genetics	2014	35
24658002	6597	Witkowski L	Germline and somatic SMARCA4 mutations characterize small cell carcinoma of the ovary, hypercalcemic type.	Nature genetics	2014	39
24658004	6597	Jelinic P	Recurrent SMARCA4 mutations in small cell carcinoma of the ovary.	Nature genetics	2014	35
9771714	6790	Zhou H	Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation.	Nature genetics	1998	306
23535731	7015	Bojesen SE	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer.	Nature genetics	2013	181
11965534	7157	Mirza A	Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway.	Oncogene	2002	130
17255760	7157	Kindelberger DW	Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.	The American journal of surgical pathology	2007	194
20229506	7157	Ahmed AA	Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.	The Journal of pathology	2010	149
24768524	7157	Bykov VJ	Mutant p53 reactivation by small molecules makes its way to the clinic.	FEBS letters	2014	32
20942669	8289	Wiegand KC	ARID1A mutations in endometriosis-associated ovarian carcinomas.	The New England journal of medicine	2010	322
24618703	8289	Wu RC	The emerging roles of ARID1A in tumor suppression.	Cancer biology and therapy	2014	29
14638851	8678	Qu X	Promotion of tumorigenesis by heterozygous disruption of the beclin 1 autophagy gene.	The Journal of clinical investigation	2003	613
19647222	8821	Gewinner C	Evidence that inositol polyphosphate 4-phosphatase type II is a tumor suppressor that inhibits PI3K signaling.	Cancer cell	2009	133
9252329	10011	Anzick SL	AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer.	Science	1997	362
10426999	10111	Zhong Q	Association of BRCA1 with the hRad50-hMre11-p95 complex and the DNA damage response.	Science	1999	123
22006311	10111	Walsh T	Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.	Proceedings of the National Academy of Sciences of the United States of America	2011	149
12839961	10406	Hellström I	The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma.	Cancer research	2003	133
21317925	10413	Zhang X	The Hippo pathway transcriptional co-activator, YAP, is an ovarian cancer oncogene.	Oncogene	2011	75
11967536	11200	Meijers-Heijboer H	Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.	Nature genetics	2002	216
16551709	11200	Walsh T	Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer.	JAMA	2006	143
24549055	11200	Castéra L	Next-generation sequencing for the diagnosis of hereditary breast and ovarian cancer using genomic capture targeting multiple candidate genes.	European journal of human genetics 	2014	39
25186627	11200	Tung N	Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.	Cancer	2015	49
25288723	11200	Kiiski JI	Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer.	Proceedings of the National Academy of Sciences of the United States of America	2014	22
26270727	11200	Desmond A	Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.	JAMA oncology	2015	24
26483394	11200	Hu C	Prevalence of Pathogenic Mutations in Cancer Predisposition Genes among Pancreatic Cancer Patients.	Cancer epidemiology, biomarkers and prevention 	2016	11
26976419	11200	Tung N	Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.	Journal of clinical oncology 	2016	10
19092150	23405	Merritt WM	Dicer, Drosha, and outcomes in patients with ovarian cancer.	The New England journal of medicine	2008	252
21205968	23405	Rio Frio T	DICER1 mutations in familial multinodular goiter with and without ovarian Sertoli-Leydig cell tumors.	JAMA	2011	43
21266384	23405	Slade I	DICER1 syndrome: clarifying the diagnosis, clinical features and management implications of a pleiotropic tumour predisposition syndrome.	Journal of medical genetics	2011	59
21882293	23405	Foulkes WD	Extending the phenotypes associated with DICER1 mutations.	Human mutation	2011	37
18156967	57534	Jarboe E	Serous carcinogenesis in the fallopian tube: a descriptive classification.	International journal of gynecological pathology 	2008	56
21285249	79728	Casadei S	Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.	Cancer research	2011	55
25455730	145270	Duffy MJ	p53 as a target for the treatment of cancer.	Cancer treatment reviews	2014	38
